Stop STALLING Act was reported by committee and awaits a floor vote
IntroducedMar 24, 2025
ReportedApr 3, 2025
Passed one chamber—
Passed both—
Law—
What it changes · CRS summary
Written by the Congressional Research Service [2]. 107 words.
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug. The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Context
- Committees
- Senate Judiciary Committee
- Policy area
- Health: 122 of 9,357 bills became law, 113th–118th (1.3%)
- Sponsor
- 17 of 637 bills enacted since 2013
- Text versions
- 2, from introduced in senate to reported to senate · 990 words
- Subjects
- Administrative remediesBusiness ethicsCivil actions and liabilityCompetition and antitrustDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulation +4 more
- Latest action
- Apr 10, 2025: Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
- Records
- Congress.gov · Bill text
Exhibit 1Passage odds band at each stage, rated when the bill reached it [4]
Related bills · 0
The bill status record lists no related bills.
Exhibit 2Articles naming the bill per day, last 90 days, US sources [3]